CriticalSecond-generation systemic triazole antifungal×Antianginal – late sodium current inhibitor
Updated · Methodology
Mechanism
The liver and gut break down ranolazine mainly through the enzyme CYP3A4 and to a lesser extent through CYP2D6 (ranolazine label, US Food and Drug Administration, FDA). Posaconazole is a strong CYP3A4 inhibitor and can markedly raise exposure to drugs that this enzyme metabolises (posaconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). The documents report no study of this pair. Another strong CYP3A4 inhibitor, ketoconazole 200 mg twice daily, increased the area under the concentration-time curve (AUC) of ranolazine 3.0–3.9-fold (ranolazine SmPC, EMA). Higher ranolazine levels raise the risk of its dose-dependent adverse effects, such as nausea and dizziness, and prolong the corrected QT interval (QTc) further (ranolazine SmPC, EMA). Posaconazole has also been associated with QT prolongation (posaconazole FDA label). The EU posaconazole SmPC says not to give posaconazole with CYP3A4 substrates that prolong the QTc interval (posaconazole SmPC, EMA).
Symptoms
Dizziness, nausea and vomiting become more frequent as the ranolazine dose rises. In an intravenous overdose study in healthy volunteers, double vision, lethargy and fainting also occurred (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Oral ranolazine overdose has caused low blood pressure, QT prolongation, slow heart rate, muscle jerks, severe tremor, unsteady gait and incoordination, dizziness, nausea, vomiting, speech difficulty and hallucinations. Extreme overdose has been fatal (ranolazine label, US Food and Drug Administration, FDA). Cases of torsade de pointes have been reported in people taking posaconazole (posaconazole FDA label). QT prolongation itself causes no symptoms and shows only on an electrocardiogram. Ventricular arrhythmias cause palpitations, dizziness and fainting.
Management
The combination is contraindicated. The EU ranolazine summary of product characteristics (SmPC) contraindicates strong inhibitors of the enzyme CYP3A4 and names posaconazole among them (ranolazine SmPC, European Medicines Agency, EMA). The US ranolazine label contraindicates strong CYP3A inhibitors, and the US posaconazole label describes posaconazole as a strong CYP3A4 inhibitor (ranolazine and posaconazole labels, US Food and Drug Administration, FDA). The US posaconazole label contraindicates CYP3A4 substrates that prolong the QT interval, and the EU SmPC says not to give posaconazole with such drugs. By its own documents, ranolazine meets both criteria (posaconazole FDA label and SmPC, EMA; ranolazine SmPC, EMA, and FDA label). No document says how long to wait after stopping posaconazole before starting ranolazine. The documents give only the mean half-life of posaconazole tablets, 29 hours (posaconazole SmPC, EMA). Monitor potassium, magnesium and calcium and correct any disturbance before and during posaconazole treatment (posaconazole SmPC, EMA, and FDA label). Ranolazine is an add-on to beta-blockers or calcium antagonists when they are not enough or not tolerated (ranolazine SmPC, EMA). With posaconazole, monitor calcium antagonists that CYP3A4 metabolises (diltiazem, verapamil, nifedipine) frequently for adverse effects and toxicity, and adjust their dose if needed (posaconazole SmPC, EMA). If ranolazine has nevertheless been taken with posaconazole and signs of ranolazine overdose appear, monitor the patient closely and give symptomatic and supportive treatment. Continuous electrocardiogram (ECG) monitoring may be needed. Haemodialysis is unlikely to clear ranolazine fully, because about 62% of it binds to plasma proteins (ranolazine SmPC, EMA, and FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- FDA: Noxafil (posaconazole) prescribing information (2026)– FDA, DailyMed, Noxafil (Merck Sharp & Dohme), setid b073b082-7b57-4423-8c06-4fd4263d6f84, versión 56, revisión 02/2026, secciones 4.2, 4.3, 4.4, 4.5, 5.2 y 7.2
- EMA: Ficha técnica: Ranolazina (EU/1/08/462), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 08462001 (EU/1/08/462), secciones 4.3, 4.5 y 4.9, consultado 10/2026
- EMA: Ficha técnica: Posaconazol (EU/1/05/320), sección 4.3 (2026)– EMA, Noxafil (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 105320002, consultada 10/2026, secciones 4.3, 4.4 y 4.5